<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Somatic mutations and the risk of undifferentiated autoinflammatory disease in MDS : an under-recognized but prognostically important complication</dc:title><dc:creator>Watad,	Abdulla	(Avtor)
	</dc:creator><dc:creator>Kačar,	Mark	(Avtor)
	</dc:creator><dc:creator>Bragazzi,	Nicola Luigi	(Avtor)
	</dc:creator><dc:creator>Zhou,	Qiao	(Avtor)
	</dc:creator><dc:creator>Jassam,	Miriam	(Avtor)
	</dc:creator><dc:creator>Taylor,	Jan	(Avtor)
	</dc:creator><dc:creator>Roman,	Eve	(Avtor)
	</dc:creator><dc:creator>Smith,	Alexandra	(Avtor)
	</dc:creator><dc:creator>Jones,	Richard A.	(Avtor)
	</dc:creator><dc:creator>Amital,	Howard	(Avtor)
	</dc:creator><dc:subject>myelodysplastic syndromes - genetics</dc:subject><dc:subject>autoinflammation</dc:subject><dc:subject>undifferentiated autoinflammatory disease</dc:subject><dc:subject>molecular characterization</dc:subject><dc:subject>somatic mutations</dc:subject><dc:description>Objectives: We theorized that myelodysplastic syndrome (MDS) with somatic mutations and karyotype abnormalities are associated with autoinflammation, and that the presence of autoinflammatory disease affected prognosis in MDS. Methods: One hundred thirty-four MDS patients were assessed for the prevalence of autoinflammatory complications and its link with karyotypes and somaticmutation status. Autoinflammatory complications were described either as well-defined autoinflammatory diseases (AD) or undifferentiated "autoinflammatory disease" (UAD) (defined as CRP over 10.0 mg/L on five consecutive occasions, taken at separate times and not explained by infection). Several patient characteristics including demographic, clinical, laboratory, cytogenetics charts, and outcomes, were compared between different groups. Results: Sixty-two (46.3%) patients had an autoinflammatory complication manifesting as arthralgia (43.5% vs. 23.6%, p = 0.0146), arthritis (30.6% vs. 15.3%, p = 0.0340), skin rash (27.4% vs. 12.5%, p = 0.0301), pleuritis (14.5% vs. 4.2%, p = 0.0371) and unexplained fever (27.4% vs. 0%, p &lt; 0.0001). AD were found in 7.4% of MDS patients (with polymyalgia rheumatic being the most frequently one). Classical autoimmune diseases were found only in 4 MDS patients (3.0%). Transcription factor pathway mutations (RUNX1, BCOR, WTI, TP53) (OR 2.20 [95%CI 1.02-4.75], p = 0.0451) and abnormal karyotypes (OR 2.76 [95%CI 1.22-6.26], p = 0.0153) were associated with autoinflammatory complications. Acute leukaemic transformation was more frequent in MDS patients with autoinflammatory features than those without (27.4% vs. 9.7%, p = 0.0080). Conclusions: Autoinflammatory complications are common inMDS. Somatic mutations of transcription factor pathways and abnormal karyotypes are associated with greater risk of autoinflammatory complications, which are themselves linked to malignant transformation and a worse prognosis.</dc:description><dc:publisher>Frontiers Media SA</dc:publisher><dc:date>2021</dc:date><dc:date>2021-03-31 14:40:29</dc:date><dc:type>Neznano</dc:type><dc:identifier>13806</dc:identifier><dc:identifier>UDK: 616.1</dc:identifier><dc:identifier>ISSN pri članku: 1664-3224</dc:identifier><dc:identifier>DOI: 10.3389/fimmu.2021.610019</dc:identifier><dc:identifier>COBISS_ID: 57751555</dc:identifier><dc:language>sl</dc:language><dc:rights>© 2021 Watad, Kacar, Bragazzi, Zhou, Jassam, Taylor, Roman, Smith, Jones, Amital, Cargo, McGonagle and Savic</dc:rights></metadata>
